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Many essential physiological pathways, such as cell proliferation, gene expression, and 
cardiovascular health are regulated by Protein Arginine Methyltransferases (PRMTs) through 
methylation of arginine residues in protein substrates. Understanding how PRMTs interact with 
their substrates is pivotal to understanding the biological role of these enzymes, and fundamental 
to the goal of identifying possible sites to be inhibited through drug therapy. Natural variations in 
the N-terminus of the PRMTl enzymes and data collected in our lab suggest that the N-terminus 
is important for activity and/or the binding of protein substrates. Preliminary data collected had 
led us to hypothesize that the negatively charged residues in the N-terminus (Nt) of PRMTl play 
an important role in substrate specificity and protein-substrate interactions. This paper details the 
exploration of this hypothesis through the creation of DNA vectors for the E. coli expression of 
mutant human PRMTl proteins in which varying negatively charged residues are mutated to 
non-charged residues. These vectors were transformed into E. coli cells and expression and 
purification of each mutant was partially optimized. Of the three hPRMTl mutants created, one 
has been kinetically characterized and the activity of this mutant on three wild type PRMTI 
substrates has been examined. The ultimate aim of this study, accompanied with ongoing studies 
in the Hevel laboratory, is to form a complete picture of how PRMTl interacts with its substrates 
and the role of the N-terminus of PRMT I in this process. 
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The post-translational modification of proteins is an important mechanism by which organisms 
are able to expand upon a limited genome. These alterations in protein structure contribute to 
vital cell signaling pathways 1• Upon receipt of a stimulus, the cell responds with a signaling 
cascade which concludes with a biological response. The appropriate post-translational 
modification of a protein to moderate function and activity is a vital mechanism to regulate 
normal cell signaling pathways and contribute to the overall health of an organism. While some 
post-translational modifications have been extensively characterized, such as phosphorylation 
and glycosylation, there is little known about the methylation of arginine residues on protein 
substrates 1• 
Protein Arginine Methyltransferases (PRMTs) are a family of enzymes that modify the 
guanidinium group of an arginine residue by the addition of a methyl group. The modification of 
proteins by methyl groups is specifically involved in many physiological pathways, including 
RNA processing, signal transduction, transcriptional regulation, and protein trans location 
1
• 
Protein Arginine Methyltransferases enzymatically transfer a methyl group to an arginine residue 
of a protein substrate via the cosubstrate S-adenosyl-methionine (AdoMet), which acts as the 
methyl group donor in the PRMT-catalyzed reaction. AdoMet is necessary for all PRMT 
reactions and is a vital cofactor in most organisms2. 
The PRMT family consists of eleven isoforms, each of which have a conserved core but differ 
extensively in the sequence of the N-terminal and C-terminal domain
3
• Three different products 
of methylation are possible: monomethylarginine, asymmetric dimethylarginine , and symmetric 
dimethylarginine (Fig 1 ). Different products of methylation can have diverse physiological 
effects, especially when normal physiological PRMT activity is disrupted. One striking example 
of this can be seen with elevated levels of asymmetric dimethylarginine (ADMA), the 
predominant product of PRMTl, which has been identified as a risk factor in cardiovascular 
disease. ADMA has also been shown to be an inhibitor of Nitric Oxide Synthase (NOS), a 
biologically relevant enzyme that is involved in the regulation of the elasticity of blood vessels
4
. 
What is most interesting, however, is that ADMA has been implicated in substantial changes in 
gene expression in human cardiac endothelial cells. These changes were independent of the 
arginine:NOS pathway, suggesting that ADMA's role exists beyond its role as a NOS inhibitor
5
• 
1 am interested in the PRMTI enzyme, which has been found to be the predominant protein 
methylation enzyme in mammals3• 
This enzyme, which produces the 
majority of endogenous ADMA 
(Figure I), is the most conserved 
isoform of PRMT and is known to 
be involved in histone methylation 
and transcriptional regulation 1• 
While many studies have been 
performed on this enzyme, it is 
still not fully understood how 
ADMA 
Figure I. Schematic diagram of the posttr anslat ional addi t ion of methyl 
group s to th e guanidinium group o f an arginin e residue via PRMTl 
utilizing AdoMet as a methyl group don or. 
1 
PRMTI interacts with its substrates 6 . 
One of the predominant goals in the Hevel 
lab is to elucidate how PRMTI interacts 
with its substrates 7. A complete 
understanding of this interaction could lend 
valuable information m identifying 
possible sites to be inhibited through drug 
therapy. Previous studies in the Hevel lab 
and in the PRMT field have suggested that 
different lengths of N-termini can alter 
substrate specificity6. In trying to elucidate 




Figure 2. Th e final prot ein produ ct of th e Ne-mutants of 
hPRMTI. Th e asterisks indi cate th e region of the N-terminu s 
th at consta ins th e glutamate to alanin e mutati ons. Th e 
Histidin e6 tag (blue box) is beside the TEV cleavage sequ ence 
(green box) , followed by th e PRMTl prot ein (indi cated by the 
purpl e box). 
specific amino acid sequence of the N-terminus was analyzed and a number of negatively 
charged amino acids in the N-terminus were identified. Because substrates of PRMTI are 
positively charged guanidinium groups, it could be possible that there is an interaction between 
the positively charged substrate and the negatively charged residues on the N-terminus. We 
hypothesize that the negatively charged amino acids of the N-terminus of hPRMTl may function 
in regulating enzymatic activity and are also involved in protein-protein interactions with 
substrates. We believe that the negatively charged amino acids in the N-terminus of PRMTI are 
important in PRMT I activity because they interact with positively charged residues of the 
protein substrate , forming a substrate orientation that is favorable for catalysis. 
The purpose of this project was to determine if the negatively charged amino acids of the N-
terminus play a role in forming a favorable substrate orientation for catalysis, which is important 
for PRMTI activity . This hypothesis was and will continue to be tested by creating a variety of 
mutants of hPRMTI in which a permutation of the negatively charged amino acids in the N-
terminus are mutated to neutral charges (glutamate residues will be mutated to alanine residues). 
First, I created vectors containing histidine-tagged hPRMTl mutants for protein expression (see 
figure 2) . Second, I optimized expression and purification of one of the hPRMTl protein 
mutants . After successful expression and purification of all of the hPRMTI mutants , I will 
incubate the mutant proteins with wild type hPRMTI substrates and obtain kinetic data for each 
mutant. This data will be compared to the kinetic data obtained from wild type hPRMTI to 
determine if there is a significant difference in protein methylation between the constructs. 
Materials and Methods: 
Creation of Histidine-tagged mutant hPRMTI genes: 
A human PRMTI mutant termed Nt~NEG, in which all five of the N-terminal glutamate 
residues (E5A, E 12A, E 19A, E22A, E27 A) were mutated to alanine residues, was ordered from 
GenScript (a gene synthesis facility). This gene arrived in a pUC57-simple vector. The vector 
was transformed into DH5a E. coli cells and the plasmid containing the Nt~NEG gene was 
purified using a DNA purification kit from Qiagen. The plasmid concentration was determined 
using a nanodrop spectrophotometer. Seven hundred ng of plasmid was digested using fast digest 
2 





Figure 3. A tabl e showing each of the primer sequences for the creat ion 
of E5A hPRMTl and E2 7 A hPRMT I constructs. BS0 I and BS02 coded 
for th e mut at ion in E5A hPRMTI and BS03 and BS04 coded for th e 
mutation in E27A hPRMTI. 
enzymes Xho I and Kpn I from 
Fermentas and then visualized using 
a 0.8% agarose gel, from which the 
successfully digested products were 
gel extracted and purified using a 
Qiagen gel extraction kit. The 
NtL'-.NEG insert was then ligated into 
previously cut pET45b + expression 
vector using T4 DNA ligase 
(Fermentas) in a 3:1 molar ends ratio 
at room temperature for 30 minutes . 
Products of the ligation reaction were transformed into DH5a E. coli cells for plasmid 
regeneration and expression. The resulting plasmid was extracted using the same Qiagen plasmid 
purification kit and sent to the Center for Integrated Biosystem 's sequencing facilities for 
confirmation of correct ligation . After sequencing data was confirmed to be correct, the NtL'-.Neg 
hPRMTI mutant was transformed into BL2 I, C4 I (from Lucigen), and NiCo21 (DE3) E. coli 
cells (from New England Biolabs). 
After successfu l creation of the NtL'-.NEG hPRMTI mutant , DNA encoding wild type hPRMTI 
in the pET45b+ vector was used to create two more ex pression vectors encoding mutant 
hPRMTI proteins. Both the E5A hPRMTI (primers BS0l and BS02) and E27A hPRMTl 
(primers BS03 and BS04) mutants were created using the QuikChange Site Directed 
Muta genesis Kit from Agilent following the exact protocol provided by the company . Following 
PCR of the vector using the correct mutag enic primers (see figure 3), the DNA was dige sted with 
DPN I fast digest enzyme to remove the original template DNA and the resulting product was 
transform ed into DH5a E. coli cells. DNA plasmid was purifi ed usin g a Qiagen kit and sent to 
sequen cing at the Center for Integrated Bio syste ms (USU) for sequencing. After verification of 
successfu l seque nc e identity, the plasmid was tran sformed into BL21 DE3 E. co li cells and a 
sma ll amount was grown to test the E.coli expression of each of these plasmids. 
Express ion Optimization: 
An E.co li colony (containing the NtL'-.NEG or other PRMTI mutan t gene within the expression 
plasmid) was used to inoculate a 50 mL Luria-Bertani (LB) starter culture. This culture was 
grown at 37 degrees Celsius for 12 hours and then I mL of the starter culture was used to 
inoculate one 500 mL culture. This culture was grown at 37 degrees Celsius until it reached an 
optical density of 0 .8, at which it was induced with 0.5 mM IPTG to express protein . After IPTG 
induction , cultures were incubated for 24 hours at room temperature and subsequently harvested 
usin g centrifugation at 8000 RPM . 0 .5 grams of each cell growth (NtL'-.NEG, E5A hPRMTI , and 
E27A hPRMTI) were resuspended (each in separate tubes) in I mL of 50 mM phosphate , 0.1 M 
NaCl , 20 mM imidazole buffer at pH 7.6 and lysed using sonication level 50% duty cycle power 
level 5. Cell lysates were harvested using centrifugation at 14,000 RPM for 20 minutes and 
supernatants were applied to 400 µL of packed Qiagen nickel sepharose resin. After a two hour 
incubation period , unbound protein was collected via centrifugation. The nickel resin was 
3 
wa shed five times with buffer containing 50 mM phosphate, 0.1 M NaCl, 20 mM imidazole (pH 
7.6) , washed five times with buffer containing 50 mM phosphate, 0 .1 M NaCl , 60 mM imidazole 
(pl-I 7.6), and then protein was eluted from the nickel sepharose resin using buffer containing 50 
mM phosphate, 0.1 M NaCl , and 250 mM imidazole (pH 7.6). Samples of each of these steps 
were collected and analyzed using SOS-PAGE electrophoresis on a 12% acrylamide gel ran at 
Buffer Name Buffer Contents (all buffers at pH 7.6) 
A 50 mM sodium phosphate 
B 50 mM sodium phosphate , 30 mM imidazole 
C 50 mM sodium phosphate , 60 mM imidazo le 
D 50 mM sodium phosphate , 100 mM imidazo le 
E 50 mM sodium phosphat e, 500 mM im idazole 
F 50 mM sodium phosphat e, 0.1 M NaCl, 1 mM OTT, 2 mM EDTA 
120 volts to stack and 180 volts for 
separation of protein bands. After staining 
with Coomassie brilliant blue stain , the 
protein with the best expression was chosen 
to proceed for initial large scale 
purification efforts. The constructs 
encoding Nt.6.Neg and E5A hPRMTl were 
put through additional optimization of 
expression and purification efforts. 
G 50 mM sodium phosphate , 0.1 M NaCl 
H 50 mM sodium phosphate , 0.1 M NaCl, 30 mM im idazole 
I 50 mM sodium phosphate, 0.1 M NaCl, 50 mM imidazole 
Purification: 
Figure 4. A tab le showing each of the buffers used in the E27A 
hPRMT I purification protocol. These buffers were used in a 
n ickel batc h bin din g puri ficatio n , a TEV cleavage protoco l, as 
well as an ion exchange colum n for the purpose ofE27A 
hPRMTI pur ificatio n . After successful expression opt1m1zation, 
E27A hPRMTl E. coli BL21 DE(3) cells 
were grown in LB broth and induced at an OD of 0.8 with IPTG . Cells were harvested using an 
ultracentrifuge at 8,000 RPM, which yielded l 6.1 grams of E27 A hPRMTl-containing cells. 
7.99 grams of these cells were resuspended in 35 mLs of Buffer A (see figure 4 for buffer 
contents of all buffers) . Cells were lysed using sonication (4 rounds of 10 pulses at 50% duty 
cycle power level 5) and centrifuged at 17000 RPM for 20 minutes . Supernatant was applied to 
2.5 mLs of equilibrated Qiagen resin (split into two tubes for maximum resin packing during 
centrifugation) and incubated for three hour s at 4 degrees centigrade . All centrifugation steps in 
the following protocol were performed at 700g for 3 minutes and each wa sh utilized IO mLs of 
buffer per tube. All unbound proteins were collected and the resin was washed five times with 
Buffer A. The resin was then washed five 
times with buffer B and five times with 
buff er C followed by five times with buffer 
D. Protein was eluted from the nickel 
sepharose resin using two mLs of buffer E 
and the elution process was repeated five 
times . Samples of each of these steps were 
collected and analyzed using SOS-PAGE 
electrophoresis on a 12% acrylamide gel. 
Fractions containing the purest E27 A 
hPRMTI were pooled and filtered before 
being placed in dialysis in buffer F and 
incubated with l 00 µL of 2.0 mg/mL TEV 
protease overnight. Cleaved protein was 
then dialyzed into buffer G before being re-
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Figure 5. A SOS-PAGE gel of expression tests of the Net.Neg 
protei n . Nrt. Neg was transformed into N iCo2 1DE(3), BL21, 
and C41 cell lines and expressed at roo m temp eratu re after 
induc tion by !PTG for 5 hours or 10 hour s (represented by a 
*) or indu ced at 0 .6 OD instead of 0 .8 (represented by a **) . 
Low levels of expression were seen in each cell type, but none 















Figure 6. The first att empted purifi cation of the Net.Neg 
protein expressed from NiCo21 (DE3) cells, the most soluble 
cell line. Ge l shows the pellet, supernatant , unb ou nd, wash 1 
(Wl) and last wash (LW) as well as elutions 1-4 (El-4). A red 
box in lanes El-E3 shows the putative Net.N eg. 
incubated over the same 2.5 mLs of re-
equilibrated Qiagen nickel sepharose resin 
and allowed to bind to the resin for three 
hours. Unbound protein was collected via 
centrifugation and the resin was then washed 
five times with IO mLs of buffer G, washed 
five times with buffer H, five times with 
buffer I, and eluted five times with 2.0 mLs 
of buffer E. Samples of each step were 
collected and ran on SOS-PAGE 
electrophoresis. Each sample containing 
E27 A hPRMTl were pooled and filtered 
before I :4 dilution (to dilute the 0.1 M 
NaCl) with buffer A. Diluted sample was 
loaded onto an equilibrated I mL mono Q 
ion exchange column purchased from GE 
healthcare. The column was washed with I 0 
mLs of buffer A before a IO mL gradient of buffer A to buffer A+ I M NaCl was applied. The 
column was then washed with buffer A+ I M NaCl for IO mLs. Fractions were collected and 
analyzed using SOS-PAGE electrophoresis. Fractions containing purified E27A hPRMTI were 
collected and filtered using a Millipore 0.22 µM filter. Filtered protein was placed in a 30 kDa 
concentrator from Millipor e and was concentrated to 1.45 mg/mL in the pres ence of I 0% 
glycero l before it was beaded and frozen at -80 degrees Celsius. 
Measurement of hPRMTl mutant activity: 
To test the ability of the E27A hPRMTl 
mutant to successfully methylate hPRMT I 
substrate s, E27 A hPRMT I was initially 
screened for activity using the R3 peptide 
and the Z ipTip method previou sly described 
by the Hevel labs. Meth ylation was 
measured by radiolabeled incorporation 
usin g tritiated SAM (S-
adenosylmethionine ). T his was mea sured 
usin g a disco ntinuous assay that measures 
the amount of methylation vs. time s. This 
assay was performed with the R3 peptide as 
well as wild type hPRMTI substrates 
hnRNPK and histone H4 at 37 degrees with 
timpoints taken at 0, 1, 2, 4, and 6 minutes. 
100 nM E27A hPRMTl enzyme was used in 
this experiment. Scintillation counting 
revealed DPMs for each of the time points , 
Figure 7. Histid ine-tagged Nt .6.Negwes tern 
blot prob ed with anti-(HIS)6 The Net.Neg 
prot ein was identified as the band that has 
had a red box placed aro und it in figure 6. 
Figure 8. Histidin e-tagged ESA 
hPRMTI western blot exposed to 
ant i-PRMTl (left) and ant-{HIS)6 
antibo dies after nickel batch binding 
purification of expressed ESA 
hPRMTl. This western blot 
confi rms the presen ce and slight 
expression of ESA hPRMTl protein. 
__ _, 
.if 
Figure 9. E27A hPRMTI before and 
after TEV cleavage of the Histidin e 
tag. The red box encompasses the 
prot ein before cleavage (left), and after 
cleavage (the right two lanes). The 
cleaved lanes also have TEV protea se 














Figure 10. SOS-PAGE gel of E27 A hPRMTI muta nt after TEV 
cleavage and Mono Q ion exchange purific ation. The E27A 
hPRMTI protein is seen purified here in low and high 
conce ntrations in lane F2 (Fraction number 2) and F3 (red box 
surrounds th e protein). 
which was subsequently converted to µM 
methylations per minute . Activity levels 
were then compared to wild type hPRMTI. 
Results: 
Ntt.Neg expression tests , identification , 
and pilot purification: 
The Ntt.Neg gene was synthesized by 
GenScript, a gene synthesis facility. After 
arrival at the Hevel lab , it was successfully 
digested out of the pUC57 simple vector 
and inserted into a pET45b + expression 
vector. The vector was then transformed 
into E. coli cells. The fully recombinant 
hPRMT I Ntt.NEG contains a hexa-
histidine tag followed by a sequence that 
is c leavab le by TEV (tobacco etch virus) protease. Small amounts of E. coli cells were grown 
and lyse d to determine presence and approximate concentration of the Ntt.Neg protein in the 
supernatant. This result was inconclusive (see figure 5). For more conclusive results , a small 
amount of E. coli cells were lysed and the supernatant from this procedure was placed over 
nickel batch binding affinity chromatography . Elutions and supernatants were analyzed by SOS -
PAG E chromatography. 
This result was also inconclusive as several bands were purified by this procedure and it was 
difficult to determine which band was the Ntt.Neg protein and which band was a contaminant 
(see figure 6). To resolve this , each elution 
was run on another SOS-PAGE gel and 
transferred to a membrane for Western Blot 
Analysis using anti-PRMTI antibody (see 
figure 7). After succe ss ful identification of a 
PRMT product , it was determined that 
exp ress ion optimization would have to be 
undertaken before this protein product would 
be able to be fully purified. 
ESA hPRMTI expression and pilot 
purification: 
The ESA hPRMT I gene was created via the 
successful mutation of hPRMT I using two 
mutagenesis primers. After sequence 
verification , the plasmid was transformed 
into E. coli cells and a small growth was 
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Figure 11. E27A hPRMTI activity assay with R3 peptide with 
and without OTT . E27A hPRMTI was assayed at 100 nM 
with the R3 peptide. Activity with OTT (dashed line) was 
.00372 pM methylations/minure and without OTT (solid 
line) it was .000628 1.1M metlwlations/minure. 
6 
Protein Substrate and 
Concentration 
hnRNPK 700 nM 
hnRNPK850 nM 
hnRNPK3000 nM 
hnRNPK 4000 nM 
H4120 nM 
H4 200 nM 
H42000 nM 
H4 3000 nM 
Methylation Rate with EZ7A 
hPRMTl 
1.07 nM CH3/min 
1.03 nM CHJmin 
2.04 nM CHJmin 
3.79 nM CHJmin 
1.74 nM CHJmin 
2.27 nM CHJmin 
3.14 nM CHJmin 
2.48 nM CHJmin 
Figure 12. Methylation rates o fE27A hPRMTl mut ant with 
Histo ne H4 and hnRNPK. After determinin g that th e assays 
requir ed th e utili zation of OTT , th e E27A hPRMTI mut ant 
was assayed with two PRMT I prote in substrates, Histo ne H4 
and hnRN PK. 
applied to nickel sepharose resin for batch 
binding affinity chromatography. Elution 
and supernatant samples were run on SDS 
page to identify purity level. It was unclear 
if the protein was purified in this 
experiment, as there were many bands of 
contaminant proteins and none of the 
proteins were of higher concentration in the 
elution samples. Samples from each of the 
steps in the batch binding process were run 
on an SDS-PAGE gel and transferred to a 
membrane for Western Blot analysis to be 
probed with anti-PRMTI and anti-(HIS) 6 
(see figure 8). This blot allowed for the 
successful identification of the ESA 
hPRMT I protein m SOS-PAGE analysis and helped to determine which elutions from the 
original batch binding purification to pool for TEV cleavage. After determining that ESA 
hPRMTI was successfully expressed, the elutions containing ESA hPRMTl were pooled 
dialyzed with TEV protease. The cleaved protein was concentrated using a I mL mono Q anion 
exchange chromatography purification as previously described. At the end of the purification 
scheme , the ESA hPRMTl protein had visible degradation and wasn't completely clean. The 
pilot expression and purification protocol has been established and the ESA hPRMT I protein 
will be purified in the next few weeks. 
E27 A hPRMTl purification and kinetic characterization: 
E27A hPRMTI was successfully created using the Quik-Change Site Directed Mutagenesis Kit 
and its sequence has been verified. E27 A hPRMTI was expressed in BL2 I DE(3) E. coli cells 
and purified using a nickel affinity batch binding technique followed by TEV protease cleavage 
(see figure 9). TEV protease and uncleaved E27 A hPRMTl was removed using another nickel 
sepharose affinity batch binding method. The purified E27 A hPRMTl was then buffer 
exchanged and concentrated using a Qiagen 1 mL mono q ion exchange column and then a 
Millipore 30 kDa concentrator. Protein was beaded and stored at -80 degrees Centigrade in I 0% 
glycerol (see figure 10). 
E27 A hPRMTl activity was then determined using the Zip Tip assay , which is a discontinuous 
methylation incorporation assay. E27 A hPRMTI was first assayed using the R3 peptide substrate 
of wild type hPRMTI both with and without the presence of OTT , a reductant. The E27 A 
hPRMTI construct had fourfold higher activity in the presence of the reductant (see figure 11). 
The E27 A hPRMTl protein was assayed with two different protein substrates, hi stone H4 and 
hnRNPK at a concentration close to Vmax and also a concentration close to Km. Rates of each 
of these were determined and compared against each other (see figure 12). 
Discussion and Future Work: 
7 
This project has resulted in the successful creation of three hPRMTI mutants, Nt~Neg, E5A 
hPRMTl, and E27A hPRMTI (see figure 2). Each of these has shown some expression in BL21 
DE(3) E. coli cells. The majority of this project was spent in the optimization of the purification 
protocol for E27A hPRMTl. Following purificati<;m, E27A hPRMTI was kinetically 
characterized with a variety of PRMTl substrates. When E27 A hPRMTl was assayed with R3, a 
peptide substrate, in the presence of the reductant DTT, activity increased fourfold. I hypothesize 
that the DTT reductant is restoring activity of previously oxidized amino acid residues. It is 
possible that these residues were oxidized during the purification process of the enzyme. This is 
consistent with other PRMT isoforms and a ratPRMTI construct that has been studied in our lab. 
One member of the Hevel laboratory is studying this through the creation of a cysteine-less 
ratPRMTl construct (which cannot be subject to oxidative damage) and will finalize the 
purification and kinetic characterization of this enzyme in the coming months . This will be 
investigated further as it may represent a natural signaling mechanism to control the activity of 
PRMTl in vivo. 
[nitial characterization studies of E27 A hPRMTl with protein substrates Histone H4 and 
hnRNPK show lower activity rates than the rates of E27 A hPRMTI with the R3 peptide. Each of 
the assays with protein substrates were performed in the presence of DTT. The activity rates of 
E27 A hPRMTl with both Hi stone H4 and hnRNPK increased substantially with higher 
concentrations of substrate , which is to be expected. These rates still need to be compared to wild 
type activity . Currently, the only data of activity that we have in the lab is on wild type full 
length hPRMTI or constructs in which portions of the N-terminus have been truncated. The 
E27 A hPRMTI construct is not comparable with E27 hPRMTI (one enzyme that has been 
kinetically characterized) because the E27 hPRMTl construct does not have the first 26 amino 
acids of the N-terminus present. To determine if the mutation (E27 A) makes a difference in 
substrate specificity, kinetic data of wild type hPRMTI must be obtained in the proper phosphate 
buffer. This will be performed in the next few weeks and comparisons will be made between the 
rates. 
Before these rates can be compared, multiple zip-tip assays will be performed to provide enough 
data to create full saturation curves, allowing us to determine specific kinetic parameters that 
help us understand how the methylation occurs at the molecular level. These assays will be 
performed on a variety of substrates and then compared with the results of the wild type 
hPRMTI assays performed. In addition to performing assays on substrates , assays with 
hypomethylated cell extracts will be performed. The hypomethylated cell extracts are mice 
embryonic stem cells that have had PRMTI knocked-out. This knock-out eliminates all 
endogenous PRMTl, ensuring that all native PRMTl substrates are not methylated. These 
assays will provide a more complete picture of the hPRMTl mutant's activity . 
The E27 A hPRMTl mutant expresses and purifies to a greater degree than the Nt~Neg hPRMTl 
or E5A hPRMTl constructs. The E27 A hPRMTl mutant expresses at a much higher rate than 
both the E5A hPRMTI construct and the Nt~Neg construct in multiple cell lines. Expression 
tests of Nt~Neg and E5A hPRMTI have been performed in three difference E. coli cell types, 
each with different expression properties , and no difference has been observed in expression 
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level. I hypothesize that this could be because of the mutations in the N-terminus of the protein , 
which is translated first by the ribosome. The mutations at the distal area of the N-terminus may 
destabilize the protein in some way. This could contribute to the reason why our previous 
attempted construct, Nt28 (a construct of just the 28 amino acids of the N-terminus), was not 
soluble or purifiable. There are additional E. coli cell lines that will be tried in the coming weeks 
to attempt to optimize expression of these cells, such as arctic express (Agilent) and codon+ 
DE(3) cells (Stratagene). Additionally, if optimization cannot be performed , large scale 
purification and purification optimization may be attempted without expression optimization. 
The E5A hPRMT I construct is more soluble than the Nt-0.Neg hPRMT 1 construct in BL2 l 
DE(3) E.coli cells. This may be because it only has one of the negatively charged residues in the 
N-terminus mutated to alanine (compared to five mutations in Nt-0.Neg). Pilot full scale 
purification has been completed and very small enzyme yields have been observed. Expression is 
extremely low and additional concentration steps will be added between each purification step in 
order to be able to see the increase in purity between each step and ensure successful cleavage by 
TEV protease. The Mono Q ion exchange chromatography step will be optimized using the Jon 
Excha nge Chromatography Principles and Methods Handbook published by Amersham 
Biosciences to opt imize the correct gradient protocol to effectively concentrate and purify this 
enzyme as much as possible. This purification protocol will be optimized in the coming weeks 
and enzy me activity will be assayed in a similar way to the activity assays performed on E27A 
hPRMTI. 
In addition to the Nt-0.Neg, E5A, and E27 A, further constructs may be made with additional 
combinations of glutamate to alanine mutations in the N-terminus if the final results of these 
three mutants do not give definitive results that help us to understand the role of the N-terminus. 
These constructs will be created one mutation at a time from the current wild type and mutant 
hPRMTI constructs using a QuikChange Site Directed Mutagenesis Kit. This kit will help us to 
create a vector to encode a protein that expresses only one ( or a few) of the mutations that 
Nt-0.NEG contains . 
Conclusion: 
In this paper, three hPRMT I mutants have been created. One mutant, E27 A hPRMTI has been 
shown to be active on protein and peptide substrates and has been kinetically characterized. Two 
mutants, E5A hPRMTI and Nt,0.Neg hPRMTI have been tested for expression and purification 
but require optimization before large enough quantities of enzyme can be obtained for kinetic 
characterization. Once all enzymes have been purified and kinetically characterized, their 
activities will be compared to wild type hPRMTl to determine what role the negative charges in 
the N-terminus have on substrate specificity. 
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